Updates and Insights in the Diagnosis and Management of DRESS Syndrome
| Autor: | Elisa Maria Schunkert, Sherrie J. Divito |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Drug
medicine.medical_specialty business.industry media_common.quotation_subject Antiviral therapy RegiSCAR Hospital-Based Dermatology (L Guggina and C Nguyen Section Editors) Drug reaction with eosinophilia and systemic symptoms (DRESS) Dermatology Disease Human leukocyte antigen medicine.disease Culprit Drug reactions SCARs Delayed-type drug hypersensitivity reactions Medicine Effective treatment Culprit drug business Intensive care medicine Adverse drug reaction Early onset media_common |
| Zdroj: | Current Dermatology Reports |
| ISSN: | 2162-4933 |
| Popis: | Purpose of review To provide updates on recent advances in the diagnosis and management of drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome. Recent findings The number of identified HLA allele associations with DRESS continues to grow. There is increasing evidence indicating viral infection, reactivation, and cross-reactivity may play key roles in disease. Translational work illuminated JAK/STAT activation in recalcitrant disease. There is expanding recognition of rapid-onset DRESS resulting from specific drugs. Summary DRESS is a severe form of adverse drug reaction with potential for significant morbidity and mortality. Recent research advances may improve clinical care. HLA screening can now be performed to prevent disease in susceptible patients and may help identify culprit drugs in the near future. Viral testing should be performed on every patient, and if positive, patients potentially treated with antiviral therapy. JAK inhibitors may be an effective treatment option for DRESS. Early onset of disease relative to drug exposure should not exclude the diagnosis of DRESS. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink